Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.
about
The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignanciesNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewFrom Q Fever to Coxiella burnetii Infection: a Paradigm Change.GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signalingIdentification of candidate B-lymphoma genes by cross-species gene expression profiling.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesElucidating Compound Mechanism of Action by Network Perturbation Analysis.Identification of the Glycosaminoglycan Binding Site of Interleukin-10 by NMR Spectroscopy.IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphomaSynthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaIncreased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapyThe diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasHigh level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphomaCerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Profile of pacritinib and its potential in the treatment of hematologic disorders.Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma.Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion.Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance.Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOPInflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.
P2860
Q27008221-6CE3A187-61F3-4FBD-8DDB-CA9622DBAD80Q27304386-6088AC9C-AED4-424A-B916-0F2A9FF49142Q30241105-5E09BD9F-1E04-4AEB-B1A3-6B45EF5C6EC1Q33585286-59CB8C8E-F7EE-4E8C-BDE1-D4689BC2F3F7Q34648812-23A13DD2-8AD0-410F-B878-79DB7ED5B773Q34826329-D0729EED-6D10-431B-9D6E-A0C444C60A87Q35018604-80655F84-8340-49EE-9A4F-5B00D1EC1084Q35132241-EB1575DC-D8B5-4CB0-AEE1-E8867B011FACQ35694439-E65D3708-5546-49EC-8F19-33CAF6BA6E2BQ35871318-37AA056C-7199-44CD-8B94-ADC494EC3C67Q35921894-4B44B093-C7EF-4416-91FC-ADE364AB338EQ36042686-96354699-0549-4AC6-B813-41F455B209E6Q36078298-0C70AB14-91D1-4DEB-B6EA-95737B0BE2A0Q36302956-0B5462B3-82AC-4B51-B2BD-B820E749A79CQ36703448-0C49DB15-6249-4B5D-8647-84DC6450D37CQ36750576-5F7568D8-A9B1-4494-8BFD-588DA74AE873Q36846723-464B3CA0-E7C6-4A91-B108-94EEBA9A4314Q36907849-C3AFA7BE-BE87-4A76-9CA7-AD17DE46144FQ37479559-C9C22E20-97E6-454A-BB5E-C35C8984F41CQ37621361-99879D80-4E31-4FCE-A662-0F469EDADC9EQ37711782-DF922A65-AA33-44CA-9883-6EA5C46074A3Q38132817-418C0DE1-F352-4ED4-845C-678626AA3C73Q38150876-469F0556-449E-4E0F-A5B1-AFBBF865236BQ38244524-CCD4F28D-6D87-49C6-80BF-236B63E223B4Q38259670-D3976285-F342-4537-A490-8DB39DD2860CQ38259725-B02125B6-1FBB-4B72-AEE0-FC5A7590E7C9Q38344066-0C0D92CB-0297-45CA-8129-7E015BFF28EDQ38376847-C21CBA80-0A9B-484A-9B42-E70CA2757209Q38757931-DDC54A45-B22A-4356-8A74-C871B55EAE0CQ38764993-C01FB5D8-D42C-4020-BADB-23A4B753642EQ38863424-DD18C6CE-D135-4955-AF7C-AAEE3DB40AF4Q39016086-A4E07BB4-4978-48D0-9EA6-4741659F5412Q39037933-DED57180-A8FD-474D-80C0-FB408D10D473Q39093915-87938AFB-AC3C-4434-A12B-36377C6FDA7AQ39237785-76910C4B-E531-441E-8D6D-1E2AD2293D21Q39987160-D7AEF6D1-7DC9-45E4-988F-51B89EDEB7FBQ41592583-A740CD97-7AB6-414E-9977-D02197929318Q42027992-3A676002-3331-4C38-9095-F09222D870CCQ42356327-187948BC-9378-4FE9-B9EB-D76DEA785695Q45756098-531C6E84-B27E-4827-9EEC-244CBA7C1527
P2860
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@ast
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@en
type
label
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@ast
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@en
prefLabel
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@ast
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@en
P2093
P2860
P1433
P1476
Elevated serum IL-10 levels in ...... m of aberrant JAK2 activation.
@en
P2093
Ahmet Dogan
Guangzhen Hu
Jing Jing Han
Linda Wellik
Mamta Gupta
Mary Stenson
Matthew Maurer
Steve Ziesmer
Thomas E Witzig
P2860
P304
P356
10.1182/BLOOD-2011-10-388538
P407
P577
2012-02-08T00:00:00Z